Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Myelin oligodendrocyte glycoprotein transduced T cell therapy - ImCyse

Next Previous
X
Search
Drug Profile

Myelin oligodendrocyte glycoprotein transduced T cell therapy - ImCyse

Alternative Names: MOG autologous T-lymphocyte cell therapy - ImCyse; MOG cytolytic CD4+ T-cell therapy - ImCyse; MOG gene therapy - ImCyse; MOG peptide gene therapy - ImCyse; MOG transduced T-cells - ImCyse; MOG-autologous CD4+ cell therapy - ImCyse; Myelin oligodendrocyte glycoprotein gene therapy - ImCyse; Myelin oligodendrocyte glycoprotein transduced T-cells - ImCyse

Latest Information Update: 28 Sep 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImCyse
  • Developer ImCyse; Rega Institute for Medical Research; Trinity College Dublin
  • Class Anti-inflammatories; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer; Infections; Multiple sclerosis; Myasthenia gravis; Rheumatoid arthritis
  • Discontinued Asthma; Graft-versus-host disease

Most Recent Events

  • 28 Sep 2021 No recent reports of development identified for preclinical development in Multiple-sclerosis in Belgium
  • 28 Sep 2021 No recent reports of development identified for research development in Infections in Belgium
  • 28 Sep 2021 No recent reports of development identified for research development in Myasthenia-gravis in Belgium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top